The Scaleup Europe Fund, with 5 billion euros in assets, is intended to close the financing gap for strategic technology companies in Europe – Picture by FGK with help of AI
Relevance for Biotech, Life Sciences and Clinical Development
Executive summary
This paper summarises the €5 billion Scaleup Europe Fund and explains why it matters for biotech and life sciences companies. The fund is a major EU-backed public-private growth equity initiative intended to close Europe’s late-stage financing gap for strategic technology companies. It is not limited to biotech, but biotech, medical technologies and wider life sciences are clearly within the strategic scope alongside artificial intelligence, quantum technologies, semiconductors, clean energy, space, advanced materials and agritech.
For the biotech sector, the fund is relevant because the most difficult financing point is often not early discovery, but the transition from promising science into late-stage clinical development, manufacturing scale-up, regulatory execution, market access preparation and international commercial expansion. These stages require large, long-duration capital commitments, and European companies have often needed to seek later-stage finance outside Europe.
The Scaleup Europe Fund is part of the European Commission’s broader EU Startup and Scaleup Strategy. The European Innovation Council Fund Board has selected EQT, the Swedish investment organisation, as preferred investment adviser and fund manager.
For biotech and clinical development stakeholders, the practical importance is that the fund may strengthen the European financing pathway for companies moving from innovation into clinical and commercial execution. If successful, it could increase demand for development planning, clinical operations, regulatory strategy, manufacturing readiness, evidence generation and specialist CRO support across Europe.
Key facts of Scaleup Europe Fund at a glance
| Item | Summary |
|---|---|
| Target size | €5 billion |
| Instrument | Scaleup Europe Fund, part of the EU Startup and Scaleup Strategy |
| Purpose | Late-stage and growth equity for promising European strategic scaleups |
| Institutional anchor | European Commission and European Innovation Council Fund |
| Preferred manager/adviser | EQT, the Swedish global investment organisation |
| Biotech relevance | Biotech, medical technologies and life sciences are within scope, although the fund also covers other deep-tech sectors |
| Expected timing | Presentation at the EIC Summit on 3 June 2026; first investments expected in autumn 2026, subject to final implementation steps |
Table 1. Overview of key facts of Scaleup Europe Fund
1. Policy background: Europe’s scaleup financing gap
Europe has a strong scientific, research and startup base, including in biopharma, medtech and translational medicine. The recurring problem is converting promising research and early-stage companies into globally competitive European businesses. This becomes especially difficult at the scaleup stage, when companies need large financing rounds, specialist infrastructure, senior operational teams and access to international markets.
Biotech illustrates the issue clearly. A company can move from academic discovery to seed or Series A funding, but the capital requirement increases sharply when it enters clinical development, CMC scale-up, manufacturing validation, patient recruitment, regulatory submissions and market-access planning. At that point, the funding need can exceed what many European public grants, local venture funds or early-stage investors are designed to provide.
The EU Startup and Scaleup Strategy is intended to address this broader structural gap through financing, regulatory, market-access and talent measures. The Scaleup Europe Fund is one of the most visible financing instruments within that agenda [1]. Its purpose is to help Europe retain the value created by European research and innovation, rather than seeing high-potential companies acquired early, relocate or depend mainly on non-European late-stage capital.
2. Overview of the Scaleup Europe Fund
The Scaleup Europe Fund is described by the European Innovation Council as a multi-billion late-stage and growth fund aimed at promising European companies in strategic technology areas. Its target size is €5 billion and it is expected to invest across EU Member States and associated countries [2][3].
This is not a traditional research grant. It is a growth equity initiative. That distinction is important for biotech. Research funding may support discovery, preclinical work or early validation. Growth equity supports the later, more expensive transition into clinical, operational and commercial scale. In biotech, this may include late-stage clinical trials, expansion into multiple territories, manufacturing scale-up, regulatory execution, medical affairs preparation and evidence-generation programmes.
The sector scope is deliberately broad. Public EIC material refers to strategic areas including artificial intelligence, quantum technologies, semiconductors, robotics and autonomous systems, energy technologies, space technologies, biotechnologies, medical technologies, advanced materials and agritech [2]. Therefore, biotech should be presented as a major relevant sector within the fund’s scope, not as the sole purpose of the fund.
3. Why this matters for biotech and life sciences
Biotech and life sciences companies are among the clearest examples of why late-stage European growth capital is needed. Development timelines are long, technical and regulatory risks are high, and clinical programmes require significant committed capital before revenues are generated. Even strong companies can struggle to fund the step from early clinical proof-of-concept to larger international studies or commercial readiness.
For biotech companies, a stronger European scaleup funding pathway could help support larger European-led financing rounds, reduce reliance on non-European investors for late-stage capital, and improve the likelihood that intellectual property, leadership teams and high-value operational activity remain in Europe.
The fund may also influence the wider life sciences ecosystem. Companies receiving significant growth capital are likely to require more robust development plans, integrated clinical operations, vendor oversight, regulatory and quality systems, manufacturing readiness, real-world evidence planning, market-access preparation and international site networks. This creates potential relevance not only for biotech companies, but also for European CROs, specialist consultants, CDMOs and other clinical development partners.
4. The European Innovation Council and the EIC Fund
The European Innovation Council is the EU’s principal instrument for supporting breakthrough innovation and deep-tech companies. It combines grant, blended finance and equity mechanisms to support high-risk innovators. The EIC Fund is the venture investment arm associated with the EIC and is designed to crowd in private investment alongside public policy objectives [5].
The existing EIC STEP Scale Up scheme provides a useful comparator. In 2026, it has a stated budget of €300 million and provides equity-only investments of €10 million to €30 million for strategic technologies [6]. The Scaleup Europe Fund is intended to operate at a substantially larger scale, addressing the later-stage financing gap beyond the ceiling of existing EIC equity instruments.
For biotech, this means the fund should be viewed as part of a wider European financing ladder. Early research grants and EIC instruments may help create and validate companies; the Scaleup Europe Fund is aimed at the later point where credible companies need much larger rounds to execute development and commercialisation strategies.
5. Role of the EIB Group
The European Investment Bank Group (EIB) related functions include investment advisory, due diligence, proposing investments and portfolio-support activity under an impact mandate [5]. These functions make the EIB Group relevant to the broader EU innovation-finance ecosystem.
The Scaleup Europe Fund is a €5 billion EU/EIC-backed public-private growth equity fund for strategic European technology companies, including biotech and medical technologies. It is linked to the EIC Fund investment architecture, in which the EIB Group plays investment advisory and due-diligence roles.
6. Selection of Swedish EQT
The European Innovation Council Fund Board has selected EQT as the preferred investment adviser and fund manager for the Scaleup Europe Fund. EQT is a Swedish-headquartered global investment organisation with experience across private equity, infrastructure, growth equity and technology investing [3][4][7].
Reuters reported that the EU selected Swedish private equity firm EQT AB to manage the newly established €5 billion Scaleup Europe Fund [4].
EQT’s own announcement states that the fund will invest across European technology scaleups spanning digital systems, industrial systems and life sciences [7]. This is important for a biotech-focused audience because it confirms that life sciences sit within the intended investment universe, even though the fund is multi-sector.
7. Practical implications for biotech companies and clinical development partners
The immediate implication is not that every biotech company will be eligible or funded. The fund is intended for scaleups, meaning companies that have moved beyond early-stage research and require substantial capital to become global leaders. The strongest fit is likely to be companies with defensible technology, strong management, credible development plans, significant European strategic relevance and the ability to absorb large growth-equity investment.
For biotech companies, this places more emphasis on readiness. Companies seeking this type of capital will need a clear clinical development plan, realistic timelines, credible operational assumptions, robust regulatory strategy, CMC and manufacturing plans, market-access thinking and a strong evidence-generation strategy. Investors at this level will expect a coherent path from science to value creation.
For CROs and clinical development partners, the fund may create a downstream opportunity. Better-financed European biotech scaleups may need partners that can deliver international clinical trial management, feasibility, site activation, regulatory coordination, vendor oversight, data strategy and quality systems. The fund could therefore increase demand for specialist partners who can help emerging companies execute complex clinical programmes efficiently.
8. Points to monitor
Several implementation questions remain important: final legal agreements, launch documents, detailed investment criteria, the balance between public-policy objectives and commercial returns, the level of private capital ultimately mobilised, geographical distribution of investments, and eligibility for companies in associated countries.
For biotech and life sciences, the most important points to monitor are whether the fund publishes sector-specific investment guidance, whether investments include therapeutics and medtech as well as broader life sciences technologies, the expected company stage, and the extent to which the fund supports companies already entering or expanding clinical development.
The first investments are expected in autumn 2026, following presentation of the fund and manager at the EIC Summit on 3 June 2026 [3][4]. Biotech stakeholders should monitor the EIC, European Commission and EQT communications for more precise eligibility and access details.
Biotech relevance of Scaleup Europe Fund: summary table
| Biotech challenge | How the fund is relevant | Why it matters for the industry |
|---|---|---|
| Large late-stage financing needs | Targets growth and scaleup capital rather than early research grants | Could help European biotech companies fund larger development and expansion phases |
| Long clinical development timelines | Designed for companies requiring substantial capital to become global leaders | Supports the type of long-horizon investment often needed in therapeutics and medtech |
| Risk of relocation or early acquisition | Aims to keep promising European scaleups anchored in Europe | May help retain IP, leadership and high-value activity in Europe |
| Operational execution burden | Invested companies will need credible plans and strong delivery partners | Creates relevance for CROs, regulatory consultants, CDMOs and clinical development specialists |
| Need for strategic autonomy | Focuses on strategic technologies including biotech and medical technologies | Positions life sciences as part of Europe’s competitiveness and sovereignty agenda |
Table 2. Summary of the relevance of Europe Scaleup Fund to the biotech Industry
CONCLUSION
The €5 billion Scaleup Europe Fund is a major EU initiative to strengthen Europe’s ability to scale strategic technology companies. It is not a biotech-only fund and should not be presented as direct EIB research funding. Its most accurate description is an EU/EIC-backed public-private growth equity fund for strategic European scaleups, managed by Swedish EQT and linked to the wider EIC Fund investment architecture.
For biotech and life sciences, the relevance is clear. These sectors are explicitly within the fund’s strategic scope and are among the areas most exposed to late-stage financing gaps. If the fund is successful, it may improve the ability of European biotech companies to progress from research and early clinical promise into larger, better-funded development and commercialisation programmes within Europe.
For clinical development stakeholders, including CROs and specialist service providers, the fund should be monitored as a potential catalyst for better-financed European biotech scaleups, larger clinical programmes and increased demand for high-quality development execution.
References:
1 European Commission, “EU Startup and Scaleup Strategy,” including description of the Scaleup Europe Fund as a €5bn initiative and launch at the EIC Summit 2026. https://research-and-innovation.ec.europa.eu/strategy/strategy-research-and-innovation/jobs-and-economy/eu-startup-and-scaleup-strategy_en
2 European Innovation Council, “Scaleup Europe Fund,” describing the fund as a multi-billion late-stage and growth fund for strategic technology areas. https://eic.ec.europa.eu/eic-fund/scaleup-europe-fund_en
3 European Commission Press Corner, “European Innovation Council selects EQT to lead €5 Billion Scaleup Europe Fund,” 17 May 2026. https://ec.europa.eu/commission/presscorner/detail/en/ip_26_1102
4 Reuters, “EU selects EQT to run its nearly $6 billion Scaleup Europe Fund,” 18 May 2026. https://www.reuters.com/business/eu-selects-eqt-run-its-nearly-6-billion-scaleup-europe-fund-2026-05-18/
5 European Innovation Council, “About the EIC Fund,” describing investment advisory, due-diligence and portfolio-management roles. https://eic.ec.europa.eu/eic-fund/about-eic-fund_en
6 European Innovation Council, “STEP Scale Up,” describing the 2026 budget and €10m-€30m equity-only investment range. https://eic.ec.europa.eu/eic-funding-opportunities/step-scale_en
7 EEQT, “EQT selected to lead the Scaleup Europe Fund,” 18 May 2026. https://eqtgroup.com/en/news/eqt-selected-to-lead-the-scaleup-europe-fund-2026-05-18
About the Author:
Mark Thomas
Managing Director FGK UK
Mark is the founder and Managing Director of Clinicology Ltd, a specialized Contract Research Organization (CRO) based in Guildford, UK, which was acquired by FGK Clinical Research in 2024. Before founding Clinicology, he was founding director and board member of a medium sized global CRO. Mark has over 30 years of experience in managing pharmaceutical and medical device studies.